Sanofi的里利普鲁巴特(Riliprubart)因治疗CIDP而获得日本孤儿的药物地位, Sanofi's Riliprubart gains orphan drug status in Japan for treating CIDP, a rare nerve disorder.

Sanofi's Riliprubart, 一种治疗CIDP的抗体, 一种罕见的神经紊乱症, 在美国和欧洲获得类似承认后, 在日本获得孤儿药物地位。 Sanofi's Riliprubart, an antibody for treating CIDP, a rare nerve disorder, received orphan drug status in Japan, following similar recognitions in the US and Europe. 尽管目前进行了治疗,但大约30%的CIDP病人仍面临弱和疲劳等症状,影响他们的生活质量。 Despite current treatments, about 30% of CIDP patients still face symptoms like weakness and fatigue, impacting their quality of life. Riliprubart正处在第三阶段试验阶段,旨在解决这些未满足的医疗需要。 Riliprubart is in Phase 3 trials and aims to address these unmet medical needs.